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The effects of recombinant human erythropoietin
(rHuEPO) administration on blood pressure and
urinary albumin excretion were studied in
normotensive Wistar-Kyoto rats (WKY), in
spontaneously hypertensive rats (SHR), and in
SHR rats treated with an angiotensin converting
enzyme inhibitor (SHR-ACEi). Rats were housed
in metabolic cages and treated with rHuEPO (150
U/kg body weight [bw] three times a week) for 6
weeks. Control animals received the vehicle only
(0.25 mL of physiological saline). An angiotensin
converting enzyme inhibitor was administered in
the drinking water for 6 weeks (spirapril 5 mg/kg
bw). Systolic blood pressure (SBP), and 24 h
urinary albumin excretion (UAE) were measured
once a week. No significant differences in SBP
were observed between rHuEPO and vehicle-
treated normotensive animals at the end of the
treatment (171.9 6 4.9 v 172.1 6 5.6 mm Hg,
respectively). After 6 weeks, SBP was significantly
higher in SHR and SHR-ACEi groups treated with
rHuEPO than in control groups (239.8 6 7.3 and
243.0 6 7.3 mm Hg v 218.1 6 6.0 and 187.9 6 4.6
mm Hg, respectively); UAE was significantly
higher in groups treated with rHuEPO than in
control groups (WKY: 265.9 6 19.5 v 127.0 6 12.3
mg/100 g bw, SHR: 1668.4 6 564.6 v 234.8 6 22.9
mg/100 g bw, and SHR-ACEi: 1522.7 6 448.3 v
143.0 6 18.9 mg/100 g bw, respectively). We
concluded that erythropoietin treatment causes an
increase in arterial pressure in SHR only, and an
increase in UAE in both normotensive and
hypertensive rats. The albuminuric effect was not
entirely dependent on increased blood pressure.
The treatment with an angiotensin converting
enzyme inhibitor did not modify either the
proteinuric or the pressor effects. Am J Hypertens
1997;10:772-778 © 1997 American Journal of
Hypertension, Ltd.
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It has been shown that the replacement therapywith recombinant human erythropoietin is effec-tive in correcting the anemia of patients withchronic renal failure1,2 and thus in abrogating
blood transfusion requirements.3–5 However, in a con-
siderable proportion of erythropoietin-treated pa-
tients, development or worsening of arterial hyperten-
sion has been described.6–8 These untoward effects
have been ascribed to an increase of peripheral vascu-
lar resistances (due to the increased blood viscosity
and to the suppression of the hypoxic vasodilatation),
which is not appropriately counterbalanced by a nor-
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mal readaptation of the cardiac output.6,9–11 In patients
with chronic renal failure, a positive history of familial
hypertension or a preexisting hypertensive state may
increase the incidence of hypertensive response to
erythropoietin therapy.12,13 Thus, it is likely that the
hypertensive effect of erythropoietin treatment may
be related either to an altered arterial pressure control
associated to the chronic renal failure or to a genetic
predisposition in developing arterial hypertension.
Although it is clear that in patients with chronic
renal failure the erythropoietin treatment increases
cardiovascular morbidity, possible adverse effects of
erythropoietin therapy in other forms of anemia (not
associated to impaired renal function) have never
been investigated in spite of the increasing use of
erythropoietin therapy in clinical practice.14–17 It is
also unknown whether a normal renal function may
prevent the increase of blood pressure related to
erythropoietin administration. In this regard, it is in-
teresting to note that, when healthy subjects were
treated with erythropoietin, blood pressure did not
increase in spite of similar increases in hematocrit and
hemoglobin.18 On the other hand, a glomerular dam-
age related to increases in hematocrit has been de-
scribed in rats,19,20 thus it would also be important to
investigate whether erythropoietin treatment is asso-
ciated with a specific renal damage.
To investigate whether the presence of intact kid-
neys can prevent the development or the worsening of
arterial hypertension during erythropoietin treatment,
the effect of erythropoietin administration on blood
pressure was studied in both normotensive and spon-
taneously hypertensive rats. In addition, in the same
animals, a possible untoward effect of erythropoietin
treatment on the kidney was investigated by measur-
ing 24-h urinary albumin excretion that is known to be
an early index of glomerular damage.21–23 Finally, in
another group of hypertensive rats, we studied
whether the hypotensive treatment with a converting
enzyme inhibitor could prevent or modify the pressor
and proteinuric effects of the erythropoietin treatment.
METHODS
The experiments were performed in conscious normo-
tensive (Wistar-Kyoto, WKY) and spontaneously hy-
pertensive (SHR) rats weighing 250 g. Animals were
individually housed in metabolic cages in a tempera-
ture-controlled room at 22° to 24°C with a 12:12 light-
dark cycle for 8 weeks. During the first 2 weeks, rats
were accustomed to the metabolic cages and to the
procedures of measuring systolic blood pressure (tail
cuff method). After this period, basal values were
collected for all variables then rats were treated with
150 U/kg body weight (bw) of human recombinant
erythropoietin (rHuEPO), subcutaneously, three times
a week for 6 weeks. Control animals received the
vehicle of rHuEPO (0.25 mL of physiological saline).
In addition to vehicle or erythropoietin treatment, a
group of spontaneously hypertensive rats was also
treated with an angiotensin converting enzyme inhib-
itor (ACEi; spirapril) for 6 weeks (SHR-ACEi). Spira-
pril was diluted in the drinking water in a concentra-
tion appropriate to approximately obtain an intake of
5 mg/kg bw/day. According to treatment the six ex-
perimental groups were: WKY-EPO (n 5 8), treated
with rHuEPO; WKY-VEH (n 5 8), treated with vehi-
cle; SHR-EPO (n 5 8), treated with rHuEPO; SHR-
VEH (n 5 8), treated with vehicle; SHR-ACEi-EPO
(n 5 8), treated with an ACEi and rHuEPO; and
SHR-ACEi-VEH (n 5 8), treated with ACEi and
vehicle.
Once a week, systolic blood pressure, body weight,
24-h water intake and 24-h urine volume were mea-
sured by the same investigator who was unaware of
the specific rat treatment. Systolic blood pressure was
assessed by indirect pressure measurements (tail-cuff
method) averaging six recordings performed in each
animal. In our experimental conditions, it was verified
that the tail cuff method overestimates values mea-
sured by direct intraarterial recordings by about
10%.24 However, original, uncorrected values are re-
ported in the results. Urinary sodium concentration
was determined by potentiometric method. Urinary
albumin concentration was measured by a radio im-
munoassay method, modified with the specific anti-
body for the albumin of rat. The 24-h urinary sodium
and albumin excretion were calculated by multiplying
urine volume times urine sodium and albumin con-
centrations, and normalized for body weight.
At the end of the sixth week of treatment animals
were killed by decapitation and 5 mL of trunk blood
were collected to measure hematocrit and hemoglobin
concentration (colorimetric method). In addition, one
kidney was removed, fixed in 10% buffered formalin,
and paraffin embedded. Coronal sections (4 mm) were
then cut and stained with hematoxylin/eosin and pe-
riodic acid-Schiff reaction for standard microscopic
examination.
Statistical Analysis Data are presented as means 6
standard error of the mean (SEM). The time course of
systolic blood pressure and urinary albumin excretion
were analyzed by one-way analysis of variance
(ANOVA) for repeated measures followed by the
Scheffe´ F procedure to detect which treatment value
was different from the basal one. Differences among
control and erythropoietin treated groups for systolic
blood pressure, urinary albumin excretion as well as
for body weight, hematocrit, hemoglobin, water in-
take, urine volume, and urinary sodium excretion
were analyzed by the unpaired t test. Differences
among the values measured in WKY, SHR, and SHR-
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ACEi groups, both in the vehicle or erythropoietin
treatment groups, were analyzed by factorial analysis
of variance followed by the Scheffe´ F procedure for
post hoc comparison. After logarithmic transforma-
tion of the urinary albumin excretion values, simple
regression analysis was performed between urinary
albumin excretion and arterial pressure and hemato-
crit values.
RESULTS
Effects of Erythropoietin Treatment on Body Weight,
Hematocrit, Hemoglobin, Water Intake, Urine Vol-
ume, and Urinary Sodium Excretion Before any
pharmacological treatment, no differences in body
weight, water intake, urine volume, and urinary so-
dium excretion were observed between the control
and rHuEPO treated groups. In hypertensive animals,
under basal conditions, water intake, urine volume,
and urinary sodium excretion were significantly lower
than values observed in normotensive animals (see
Table 1). As shown in Figures 1 and 2, after 6 weeks of
treatment with erythropoietin, there were no differ-
ences in body weight, water intake, urine volume, and
urinary sodium excretion between control and eryth-
ropoietin treated animals. Hematocrit and hemoglo-
bin concentrations were significantly higher in the
erythropoietin treated animals than in control rats
(Figure 1). These hematologic effects were equal in
normotensive and hypertensive rats, and they were
not modified by the concomitant administration of the
angiotensin converting enzyme inhibitor. Treatment
with ACEi increased urinary sodium excretion in SHR
rats to values similar to those of WKY rats indepen-
dently from the administration of erythropoietin (Fig-
ure 2).
Effect of Erythropoietin Treatment on Blood Pres-
sure and Urinary Albumin Excretion in WKY Rats
Although data were collected every week, values
shown in Table 2 refer to four measurements being
representative of the whole time course. In basal con-
ditions before any pharmacological treatment, systolic
blood pressure of the WKY-EPO and WKY-VEH
groups was similar. Subsequently, arterial pressure
increased in both groups of animals slightly but not
significantly. At no time were significant differences in
systolic arterial pressure between control and erythro-
poietin groups observed.
Under basal conditions, urinary albumin excretion
was higher in the WKY-EPO group than in the WKY-
VEH group, but this difference was not statistically
significant. After the second week erythropoietin
treatment caused a progressive increase in urinary
albumin excretion so that, after 6 weeks of treatment,
urinary albumin excretion values were significantly
larger than basal values. On the contrary, in the con-
trol group, urinary albumin excretion was unchanged
or slightly decreased during the 6 weeks of treatment.
Furthermore, after the second week of treatment, uri-
nary albumin excretion of the erythropoietin-treated
group was significantly larger than urinary albumin
excretion of the control group.
Effect of Erythropoietin Treatment on Blood Pres-
sure and Urinary Albumin Excretion in SHR Rats
In basal conditions (Table 2), there were no differences
in systolic blood pressure and urinary albumin excre-
tion between the SHR-VEH and SHR-EPO groups.
During the following weeks, systolic arterial pressure
slightly, but not significantly, increased in the SHR-
VEH group. In the SHR-EPO group systolic blood
pressure markedly increased, and it became signifi-
cantly higher than blood pressure of the control group
after the second week of treatment with erythropoi-
etin.
In the SHR-VEH group, during the 6 weeks of the
experimental period, urinary albumin excretion
slightly increased and it was significantly larger than
basal values at the sixth week. In the erythropoietin-
treated rats, urinary albumin excretion markedly in-
TABLE 1. BASAL VALUES OF WATER INTAKE, URINE VOLUME, SODIUM EXCRETION, AND BODY
WEIGHT IN NORMOTENSIVE RATS (WKY), HYPERTENSIVE RATS (SHR), AND HYPERTENSIVE RATS
RECEIVING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (SHR-ACEI)
WKY SHR SHR-ACEi
VEH EPO VEH EPO VEH EPO
Water intake
(mL/24 h/100 g) 15.6 6 0.6 14.6 6 0.2 12.5 6 0.5 11.7 6 0.8 13.4 6 0.6 12.7 6 0.4
Urine volume
(mL/24 h/100 g) 7.0 6 0.8 5.5 6 0.4 3.9 6 0.5 3.9 6 0.4 3.7 6 0.3 4.0 6 0.2
Sodium excretion
(mEq/24 h/100 g) 662.4 6 42.2 636.1 6 28.1 418.5 6 20.6 437.6 6 28.9 497.7 6 21.4 554.3 6 24.6
Body weight (g) 242.8 6 1.4 243.8 6 3.2 272.1 6 3.8 275.8 6 5.5 243.8 6 4.7 244.2 6 4.9
Each value represents the mean 6 SEM of eight animals. VEH, vehicle; EPO, erythropoietin.
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creased and it was significantly larger than in SHR-
VEH rats after the second week of treatment. At the
end of the pharmacological treatment, urinary albu-
min excretion was eightfold higher in the SHR-EPO
group than in the SHR-VEH rats.
Effect of Erythropoietin on Blood Pressure and Uri-
nary Albumin Excretion in SHR-ACEi Groups In
basal conditions (Table 2), before any pharmacological
treatment, systolic arterial pressure of the SHR-ACEi-
VEH group was slightly, but not significantly, higher
than the arterial pressure of the SHR-ACEi-EPO
group. During the second week of treatment with the
converting enzyme inhibitor, systolic blood pressure
of the SHR-ACEi-VEH group significantly decreased
and it remained lower than basal values for the whole
period of treatment. In animals simultaneously treated
with ACEi and erythropoietin, systolic blood pressure
progressively increased and, after the second week of
treatment, it was significantly higher than in the con-
trol group.
Under basal conditions, urinary albumin excretion
was higher in the SHR-ACEi-EPO group than in the
SHR-ACEi-VEH group, but this difference did not
reach the statistical significance. During the following
weeks, in rats treated with ACE only, a slight, but not
significant, decrease of urinary albumin excretion was
observed. In the SHR-ACEi-EPO group, the erythro-
poietin treatment caused a large increase of urinary
FIGURE 1. Graphs showing the values of body weight (BW),
hematocrit (Hct), and hemoglobin (Hb) measured after 6 weeks of
treatment with erythropoietin (heavy shading) or vehicle (light
shading) in normotensive (WKY), hypertensive (SHR), and an-
giotensin converting enzyme inhibitor treated hypertensive rats
(SHR-ACEi). Each bar represents the mean 6 SEM of eight
animals. *P , .05 between erythropoietin and vehicle treated
animals (unpaired t test).
FIGURE 2. Graphs showing the values of water intake, urine
volume, and urinary sodium excretion measured after 6 weeks of
treatment with erythropoietin (heavy shading) or vehicle (light
shading) in normotensive (WKY), hypertensive (SHR), and an-
giotensin converting enzyme inhibitor hypertensive rats (SHR-
ACEi). Each bar represents the mean 6 SEM of eight animals. *P
, .05 v WKY and SHR-ACEi animals (factorial ANOVA 1
Scheffe´ F procedure).
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albumin excretion that was significantly higher than
control values after the fourth week of treatment. At
the end of the pharmacological treatment, urinary al-
bumin excretion was tenfold higher in the erythropoi-
etin treated than in the control rats.
Histologic Findings At least two coronal sections of
each kidney were examined nonquantitatively by light
microscopy. The examiner was not aware of the strain
or treatment of the rat. No differences were detected in
the number of lesions between control and erythro-
poietin treated rats in either the SHR or WKY groups.
Correlations Between Arterial Pressure and Urinary
Albumin Excretion In spontaneously hypertensive
rats, treated or not with ACEi, the administration of
erythropoietin caused an increase of both the systolic
arterial pressure and the urinary albumin excretion. In
these animals a significant correlation between sys-
tolic arterial pressure and urinary albumin excretion
was found (Figure 3).
DISCUSSION
These experiments show that the erythropoietin treat-
ment elicits an increase in blood pressure in sponta-
neously hypertensive rats only. Despite similar in-
creases in hematocrit and, therefore, in blood viscos-
ity, arterial pressure does not change in normotensive
rats that underwent erythropoietin treatment. Our
data also demonstrate that the erythropoietin admin-
istration causes a significant increase in urinary albu-
min excretion not only in spontaneously hypertensive
animals but also in normotensive rats.
Our results on the hypertensive effect of erythropoi-
etin are in agreement with pervious data by Susic and
associates25 showing that upward and downward
chronic hematocrit changes did increase or decrease
blood pressure in hypertensive rats only, whereas the
same maneuvers did not affect blood pressure in nor-
motensive rats.
An increase in hematocrit may influence hemody-
namics either by a direct effect on blood viscosity, and
consequently on total peripheral resistances, or by an
indirect effect on local vascular tone, due to an in-
crease of oxygen delivery to tissues resulting from the
increased hemoglobin blood concentration. Indeed, an
increase in hemoglobin concentration may decrease
nitric oxide production from endothelial cells.26,27 Nev-
ertheless, the pressor response to erythropoietin treat-
ment, being evident in SHR strain only, appears to be
dependent on conditions of altered blood pressure
control. The precise mechanism underlying this phe-
nomenon remains unclear. An altered control of arte-
rial pressure may be genetically determined or the
consequence of the cardiovascular damage due to the
preexisting hypertensive state. It is also possible that
spontaneously hypertensive rats are not able to appro-
priately decrease cardiac output when peripheral vas-
cular resistances increase. As described in patients
who develop pressor response to erythropoietin
therapy,28 spontaneously hypertensive rats might have
an increased vascular reactivity to changes in oxygen
delivery. Besides an increase in hematocrit, other
mechanisms may be implicated to explain the increase
in peripheral vascular resistances following erythro-
poietin treatment. In an in vitro model it has been
suggested that erythropoietin exerts a direct vasopres-
sor effect on isolated proximal resistance vessels of the
kidney and mesenteric vasculature29; it was shown
TABLE 2. EFFECTS OF ERYTHROPOIETIN TREATMENT ON SYSTOLIC BLOOD PRESSURE AND URINARY
ALBUMIN EXCRETION IN NORMOTENSIVE (WKY), HYPERTENSIVE RATS (SHR), AND HYPERTENSIVE
RATS RECEIVING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (SHR-ACEI)
WKY SHR SHR-ACEi
VEH EPO VEH EPO VEH EPO
SBP (mmHg)
Basal 162.4 6 5.8 159.4 6 6.1 209.0 6 4.2 204.4 6 4.2 212.4 6 2.1 204.3 6 4.6
Week 2 167.8 6 6.7 158.8 6 7.7 204.6 6 3.2 219.3 6 3.8† 192.4 6 5.4* 203.4 6 4.0
Week 4 169.4 6 7.0 172.6 6 6.5 215.5 6 5.7 242.1 6 6.0*† 205.6 6 3.9 230.4 6 5.1*†
Week 6 172.1 6 5.6 171.9 6 4.9 218.1 6 8.2 239.8 6 7.3*† 187.9 6 4.6* 243.0 6 7.3*†
UAE (mg/24 h/
100 g)
Basal 138.2 6 12.5 175.2 6 15.5 145.6 6 14.8 156.4 6 11.4 176.2 6 14.4 253.9 6 56.3
Week 2 100.8 6 7.7 128.1 6 8.0† 151.9 6 9.6 195.5 6 7.8† 170.7 6 11.8 285.7 6 64.0
Week 4 90.8 6 6.5* 186.9 6 13.7† 200.6 6 22.7 870.3 6 248.7† 133.7 6 21.0 730.3 6 173.4†
Week 6 127.2 6 12.3 265.9 6 19.5*† 234.8 6 22.9* 1668.4 6 564.6*† 143.0 6 18.9 1522.7 6 448.3*†
Each value represents the mean 6 SEM of eight animals. SBP, systolic blood pressure; UAE, urinary albumin excretion normalized to body weight; VEH,
vehicle; EPO, erythropoietin.
* P , .05 versus the corresponding basal value; †P , .05 between erythropoietin and vehicle treated animals.
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also that erythropoietin treatment induces stimulation
of endothelin 1.30 Recently, Hand and colleagues31 have
demonstrated that erythropoietin treatment increases
the impaired vascular responsiveness to norepineph-
rine in hemodialysis patients. Although it has been
suggested that the renin-angiotensin system may con-
tribute to the pathogenesis of the hypertensive effect of
erythropoietin administration,32,33 our results do not
confirm the possibility that the renin angiotensin system
may play an important role in mediating the pressor
effect of the erythropoietin administration. Indeed treat-
ment with an ACEi does not prevent the increase of
arterial pressure following erythropoietin treatment. In
our experimental conditions, a role of the renin-angio-
tensin system seems limited to mediate the sodium re-
tention in hypertensive rats, as ACEi treatment signifi-
cantly increased urinary sodium excretion to a level
equal to that observed in normotensive rats. In addition
our data indicate that, a normal renal function does not
prevent the increase of blood pressure related to eryth-
ropoietin administration.
The increase in urinary albumin excretion, follow-
ing the erythropoietin treatment, can be the conse-
quence of the concomitant increase in blood pressure,
as suggested by the positive correlation between arte-
rial pressure and urinary albumin excretion observed
in hypertensive rats. On the other hand, in normoten-
sive rats treated with erythropoietin no correlation
between arterial pressure and urinary albumin excre-
tion was found, because urinary albumin excretion
increased in spite of no changes in arterial pressure.
Mechanisms other than arterial pressure should be
claimed to explain the increased urinary albumin ex-
cretion observed in normotensive animals. As it has
been demonstrated that both acute and chronic
changes in hematocrit can impair renal and glomeru-
lar function,20 it is likely that the erythropoietin-in-
duced increase in hematocrit may play a role in me-
diating the increased urinary albumin excretion. In-
deed, a significant correlation between hematocrit and
urinary albumin excretion was found at the sixth week
of treatment, when all erythropoietin-treated animals
(both normotensive and hypertensive rats) were ana-
lyzed (data not shown). Although our experiments do
not establish the mechanisms by which an increase in
hematocrit promotes albuminuria, a reasonable expla-
nation might be an increase in glomerular pressure
secondary to the increased hematocrit.20 Thus, it is
possible that both arterial pressure and hematocrit
increases elicit the albuminuric effect by the same
mechanism: an increase in glomerular pressure. ACEi
treatment at a dosage that was effective in preventing
the spontaneous increase in arterial pressure and uri-
nary albumin excretion did not modify the proteinuric
effect caused by the erythropoietin administration.
This finding suggests that angiotensin II is not the
major mechanism mediating the glomerular effect of
erythropoietin treatment.
Microalbuminuria is considered to be an index of
glomerular vascular damage.21,22 Our data, by indicat-
ing that erythropoietin treatment increased urinary
albumin excretion also in normotensive animals with
a normal renal function, suggest that urinary albumin
excretion might be a sensitive and early marker of
vascular damage during erythropoietin treatment.
In conclusion, our results show that the hyperten-
sive effect of erythropoietin treatment, likely mediated
by the increased viscosity, is evident in hypertensive
rats only. The administration of erythropoietin causes
an increase of urinary albumin excretion that is not
entirely dependent on the concomitant increase in ar-
terial pressure, both in hypertensive and normoten-
sive rats. Other mechanisms, such as the increased
hematocrit, might explain this side effect.
FIGURE 3. Scattergrams showing the relation between the val-
ues of systolic blood pressure (SBP) and urinary albumin excretion
(UAE) measured during 6 weeks of treatment with erythropoietin
in hypertensive (SHR n 5 56) and angiotensin converting enzyme
inhibitor treated hypertensive rats (SHR-ACEi n 5 56). The
correlation coefficient (r) and the significance (P) are shown for
each scattergram.
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